ARA-290 vs BPC-157
Both are sold as repair peptides, but only ARA-290 has randomized human data behind it. BPC-157's entire case is rodent, and neither molecule is approved.
Short answer
The evidence gap decides this one. ARA-290 has human clinical data behind it, while BPC-157 has only preclinical or minimal evidence, resting mostly on animal or lab work. Someone focused on neuropathy and tissue repair has trial data to go on with ARA-290; BPC-157, marketed for healing, recovery and gut health, is still an early-research option.
ARA-290
Cibinetide
An EPO-derived tissue-protective peptide with small but real human small-fiber-neuropathy data in sarcoidosis — still investigational and unapproved.
Full ARA-290 evidence reviewBPC-157
Almost entirely animal data; no validated human dose and no controlled efficacy trials.
Full BPC-157 evidence reviewARA-290 vs BPC-157: head to head
- FDA status / approved use
ARA-290
Investigational and not approved anywhere; sold online as an unregulated research peptideBPC-157
Not an approved drug anywhere; typically sold labeled for research use only- Marketed for
ARA-290
Neuropathy, tissue repairBPC-157
Healing, recovery, gut health- Outcome areas
ARA-290
Injury recovery / tissue repairBPC-157
Injury recovery / tissue repair; Gut health- Evidence grade
ARA-290
Clinical dataBPC-157
Preclinical / minimal- How it works
ARA-290
Activates the tissue-protective EPO repair receptor without raising red blood cell productionBPC-157
Appears to act on multiple repair pathways, including nitric-oxide and vascular systems- Route and dosing
ARA-290
Subcutaneous injection daily in a Phase 2 trial; IV in othersBPC-157
Injection; no established human dose- Headline human result
ARA-290
Small-fiber neuropathy score fell 11.5 points vs 2.9 on placebo in a 22-patient sarcoidosis pilot RCTBPC-157
Not established- Strongest evidence
ARA-290
Heij, Mol Med 2012ARA-290 evidence reviewPubMed 23168581BPC-157
Pharmaceutics review, 2026. Little or no controlled human outcome data for the marketed useBPC-157 evidence reviewPubMed 42198317- Key safety signal
ARA-290
No long-term safety data; trials were small and dosed for about 4 weeksBPC-157
No human safety profile; research-grade products carry contamination, mis-dosing and mislabeling risks- How it is obtained
ARA-290
Legitimately available only inside clinical trials; vials sold online are gray-market research chemicalsBPC-157
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| ARA-290 | BPC-157 | |
|---|---|---|
| FDA status / approved use | Investigational and not approved anywhere; sold online as an unregulated research peptide | Not an approved drug anywhere; typically sold labeled for research use only |
| Marketed for | Neuropathy, tissue repair | Healing, recovery, gut health |
| Outcome areas | Injury recovery / tissue repair | Injury recovery / tissue repair; Gut health |
| Evidence grade | Clinical data | Preclinical / minimal |
| How it works | Activates the tissue-protective EPO repair receptor without raising red blood cell production | Appears to act on multiple repair pathways, including nitric-oxide and vascular systems |
| Route and dosing | Subcutaneous injection daily in a Phase 2 trial; IV in others | Injection; no established human dose |
| Headline human result | Small-fiber neuropathy score fell 11.5 points vs 2.9 on placebo in a 22-patient sarcoidosis pilot RCT | Not established |
| Strongest evidence | Heij, Mol Med 2012ARA-290 evidence reviewPubMed 23168581 | Pharmaceutics review, 2026. Little or no controlled human outcome data for the marketed useBPC-157 evidence reviewPubMed 42198317 |
| Key safety signal | No long-term safety data; trials were small and dosed for about 4 weeks | No human safety profile; research-grade products carry contamination, mis-dosing and mislabeling risks |
| How it is obtained | Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
ARA-290 (cibinetide) has the stronger evidence: small Phase 2 trials in sarcoidosis-associated small-fiber neuropathy showed improved symptoms and increased corneal nerve fiber measures, and a separate Phase 2 in type 2 diabetes suggested improvement in neuropathic symptoms; these were separate trials rather than any comparison against BPC-157, and each was small, on the order of a few dozen patients dosed for about four weeks. BPC-157 has no published randomized controlled trial in humans for any indication, which means no established dosing, no long-term safety profile, and no human pharmacokinetics, and the FDA flagged it in 2023 as ineligible for compounding. ARA-290 remains investigational and is not approved by any regulator, and what circulates online as either peptide is unregulated material, not the clinical-grade product used in trials.
ARA-290 fits if
ARA-290 is the better fit for a reader interested in nerve repair who wants a molecule with real, if small and short, randomized human proof-of-concept.
BPC-157 fits if
BPC-157 is the one to read if your question is tendon, muscle, or gut recovery, with the understanding that the whole case is rodent and the product is unregulated.
ARA-290 vs BPC-157: common questions
- Is either ARA-290 or BPC-157 FDA-approved?
- No. ARA-290 is investigational and not approved anywhere; sold online as an unregulated research peptide. BPC-157 is not an approved drug anywhere; typically sold labeled for research use only.
- Which has stronger human evidence, ARA-290 or BPC-157?
- ARA-290. It has human clinical data (key source: Heij, Mol Med 2012), while BPC-157 has only preclinical or minimal evidence (key source: Pharmaceutics review, 2026).
- What are the main safety concerns with ARA-290 and BPC-157?
- ARA-290 has no long-term safety data; trials were small and dosed for about 4 weeks. BPC-157 has no human safety profile; research-grade products carry contamination, mis-dosing and mislabeling risks.
Key studies behind each
ARA-290
- Collino M, Thiemermann C, Cerami A, Brines M. (2015). Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther. PubMed 25728128
- Hache G, Garrigue P, Bennis Y, Stalin J, Moyon A, et al. (2016). ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability. Shock. PubMed 27172159
- Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, et al. (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. PubMed 23168581
- Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, et al. (2017). Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. PubMed 28475703
BPC-157
- Sikiric P, Sever M, Krezic I, et al. (2024). New studies with stable gastric pentadecapeptide protecting gastrointestinal tract: significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. PubMed 38980576
- Gwyer D, Wragg NM, Wilson SL. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. PubMed 30915550
- McGuire FP, Martinez R, Lenz A, et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. PubMed 40789979
- Bilic Z, Gojkovic S, Kalogjera L, et al. (2021). Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide BPC 157 in rats with perforated stomach through modulation of the nitric-oxide system. J Physiol Pharmacol. PubMed 35485358
The full evidence reviews
- ARA-290 (cibinetide): the EPO-derived repair peptide and what its trials actually show
An 11-amino-acid peptide engineered from erythropoietin to protect tissue without making red cells. A straight read of the small-fiber-neuropathy evidence — and its limits.
Updated August 2026
- BPC 157: what the evidence actually shows (and what it doesn't)
The 'healing peptide' has a deep rodent literature and almost no human data. A straight read of where the science stands.
Updated October 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm ARA-290 (Cibinetide) availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: Believe HealthGoldspan HealthLean MedsLongevixxMagnolia Regenerative MedicineMondae